识别患有未确诊遗传病的儿科患者的临床决策支持 (SIGHT)
评估 EHR 预测模型以识别患有未确诊遗传病的儿科患者的随机对照试验”
This study will evaluate the effectiveness of SIGHT as a clinical support system to prompt provider/patient discussion and shared decision making regarding the need for genetic testing in the form of a chromosomal microarray. Identifying patients at high predicted probability of needing a test in clinical settings will be examined to determine if it decreases the duration of time to testing and increases diagnostic yield. SIGHT requires only data already collected in routine clinical encounters and is calculated prior to a clinical visit at VUMC.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- Vanderbilt University Medical
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- All patients > 1 year old, < 20 years of age with a scheduled visit to the VUMC pediatric primary care.
Exclusion Criteria:
- Patients who have been programmatically excluded due to having already received a chromosomal microarray at VUMC and patients > 20 years of age or < 1 year of age.
学习计划
研究是如何设计的?
设计细节
- 主要用途:放映
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intervention
SIGHT predictions will be generated prior to a scheduled encounter in one of the participating study clinics. Patients with a SIGHT probability above a predefined risk level (0.30 predicted risk based on validation and prior chart review by a genetic counselor, Morley et al, 2021 below) will prompt randomization to the standard care or SIGHT-guided intervention arm. For patients randomized to the SIGHT-guided intervention arm, the clinician responsible for care in that encounter (determined in the usual course of care) will receive a message for that patient and details as to the contributing clinical features that led to the high probability. The message will include a recommendation, but providers will have full discretion to offer genetic testing or refer to genetics providers. The management of screening will follow standard of care at VUMC. |
Among patients surpassing a 0.30 probability threshold that have a scheduled visit to pediatric primary care at VUMC, 500 will be randomized to the intervention and a SIGHT-prompted provider message will be generated. |
|
无干预:Comparator
All remaining patients will be the comparator arm which will be standard of care as to avoid ethical situations of withholding potentially important care. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Diagnoses in the intervention arm compared to the control arm
大体时间:2 years
|
Number of patients diagnosed via a Chromosomal Microarray. |
2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to test
大体时间:2 years
|
Duration of time to genetic testing. Time to event, measured from the initial patient visit to the time genetic testing is conducted. |
2 years
|
|
Abnormal CMA
大体时间:2 years
|
Number of patients flagged by SIGHT who's CMA result returned abnormal but in the absence of diagnostic findings. |
2 years
|
|
Rate of genetic testing
大体时间:2 years
|
Rates of genetic testing ordered by providers after a pediatric visit. |
2 years
|
|
Diagnosis via any test (molecular confirmation)
大体时间:2 years
|
Number of patients flagged by SIGHT who receive a diagnosis via any molecular test. |
2 years
|
合作者和调查者
调查人员
- 首席研究员:Douglas Ruderfer, PhD、Vanderbilt University Medical Center
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 241678
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Patients in this study will receive standard of care at Vanderbilt University Medical Center (VUMC) and will not be consented for research participation. As a result, no individual participant data (IPD) will be made available for sharing with other researchers.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.